Fairvalue-Calculator Fairvalue-Calculator
EN DE

Healtheuniverse, Inc (HLUN) Fair Value & Analysis

Healthcare · US · Market cap $11.8K

Price$0.0001
Fair Value$0.0001
Upside+0.0%
Quality85/100
Evidence: Medium Range $0.0001 – $0.0001

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Healtheuniverse, Inc (HLUN) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 85/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Healtheuniverse, Inc., a biotechnology development company, engages in the research, development, and commercialization of biopharmaceutical, biomedical, nutraceutical, and cosmeceutical products. The company develops stem cell and regenerative medicine therapies utilizing non-embryonic adult stem cells for use in plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. It also provides consulting services to various businesses in the areas of marketing, business organization, and raising capital for business ventures. The company was founded in 2001 and is headquartered in Covina, California.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Healtheuniverse, Inc (HLUN) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001 — about +0% (undervalued). Model-based estimate, not financial advice.
What is the fair value of HLUN?
Our 21-model fair value for Healtheuniverse, Inc is $0.0001 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0001.
What is the quality score of HLUN?
Healtheuniverse, Inc has a Quality Score of 85/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.